1. Home
  2. ERH vs CGEN Comparison

ERH vs CGEN Comparison

Compare ERH & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERH
  • CGEN
  • Stock Information
  • Founded
  • ERH 2004
  • CGEN 1993
  • Country
  • ERH United States
  • CGEN Israel
  • Employees
  • ERH N/A
  • CGEN N/A
  • Industry
  • ERH Finance/Investors Services
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ERH Finance
  • CGEN Health Care
  • Exchange
  • ERH Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • ERH 108.0M
  • CGEN 125.3M
  • IPO Year
  • ERH N/A
  • CGEN 2000
  • Fundamental
  • Price
  • ERH $12.94
  • CGEN $1.61
  • Analyst Decision
  • ERH
  • CGEN
  • Analyst Count
  • ERH 0
  • CGEN 0
  • Target Price
  • ERH N/A
  • CGEN N/A
  • AVG Volume (30 Days)
  • ERH 23.2K
  • CGEN 554.1K
  • Earning Date
  • ERH 01-01-0001
  • CGEN 11-10-2025
  • Dividend Yield
  • ERH 8.85%
  • CGEN N/A
  • EPS Growth
  • ERH N/A
  • CGEN N/A
  • EPS
  • ERH N/A
  • CGEN N/A
  • Revenue
  • ERH N/A
  • CGEN $22,144,000.00
  • Revenue This Year
  • ERH N/A
  • CGEN N/A
  • Revenue Next Year
  • ERH N/A
  • CGEN $208.08
  • P/E Ratio
  • ERH N/A
  • CGEN N/A
  • Revenue Growth
  • ERH N/A
  • CGEN N/A
  • 52 Week Low
  • ERH $7.97
  • CGEN $1.13
  • 52 Week High
  • ERH $10.91
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • ERH 66.70
  • CGEN 44.74
  • Support Level
  • ERH $12.60
  • CGEN $1.61
  • Resistance Level
  • ERH $12.98
  • CGEN $1.80
  • Average True Range (ATR)
  • ERH 0.16
  • CGEN 0.14
  • MACD
  • ERH -0.00
  • CGEN -0.03
  • Stochastic Oscillator
  • ERH 92.11
  • CGEN 1.03

About ERH Allspring Utilities and High Income Fund

Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: